Hostname: page-component-77c89778f8-m42fx Total loading time: 0 Render date: 2024-07-21T21:27:48.290Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment pathways for bipolar disorder in the USA and Europe: convergence or divergence?

Published online by Cambridge University Press:  16 April 2020

Charles Bowden  and
Patrice Boyer
Charles Bowden*
Affiliation:
University of Texas Health Science Center, San Antonio, TX, USA
Patrice Boyer
Affiliation:
Pavillon Clerambault, UMR 7593 CNRS, Hôpital de la Salpétrière, Paris, France
*
*Corresponding author. bowdenc@uthsca.edu (C. Bowden).
Get access

Extract

Mood stabilising therapy is the cornerstone of treatment for bipolar disorder, a disease that is commonly associated with disabling psychosocial morbidity [37,11]. A variety of drugs have been approved for use in bipolar disorder, thus providing a wide array of options for clinicians when deciding on a course of treatment [28]. In order to assist clinical decision-making, facilitate optimal quality of care and reduce unnecessary variation in clinical practice, several clinical practice guidelines and treatment algorithms have been developed [4,19,20,21]. As well as similarities, there are some differences between guidelines developed from an American perspective and those developed from a European perspective [4,19], and there is a pervasive view in the clinical community that treatment of patients with bipolar disorder differs substantially between the United States (US) and Europe. This article discusses what is known about the similarities and differences of treatment practices for bipolar disorder between the US and Europe.

Type
Research Article
Information
European Psychiatry , Volume 18 , Issue S1 , December 2003 , pp. 19s - 24s
Copyright
Copyright © European Psychiatric Association 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allison, DBCasey, DEAntipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(7):22–31.Google ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual for mental disorders (DSM-IV). American Psychiatric Association, Washington DC; 1994.Google Scholar
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151(12):1-36.CrossRefGoogle Scholar
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 2002;159(4):1-50.Google Scholar
Angst, JThe emerging epidemiology of hypomania and bipolar II disorder. J Affective Disord 1998;50:143–51.CrossRefGoogle ScholarPubMed
Blanco, CLaje, GOlfson, MMarcus, SCTrends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002;519(6): 1005–10.CrossRefGoogle Scholar
Bowden, CLCalabrese, JRMcElroy, SLGyulai, LWassef, APetty, Fet al.A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57(5):481–9.CrossRefGoogle ScholarPubMed
Bowden, CLCalabrese, JRSachs, GSwann, AAkthar, S DeVeaugh-Geiss, JA randomized, placebo-controlled 18-month trial of lamotri-gine and lithium maintenance treatment in recently manic or hypo-manic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392–400.CrossRefGoogle ScholarPubMed
Calabrese, JRBowden, CLSachs, GYatham, LNBehnke, K Mehto-nen, OPet al.A placebo-controlled 18-month trial of lamotngine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013–24.CrossRefGoogle ScholarPubMed
Colom, FVieta, E Martinez-Aran, AReinares, MGoikolea, JMBenabarre, Aet al.A randomized trial on the efficacy of group psy-choeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60(4):402–7CrossRefGoogle ScholarPubMed
Coryell, WScheftner, WKeller, MEndicott, JAkiskal, HThe enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993; 150(5):720–7.Google ScholarPubMed
Fenn, HHRobinson, DLuby, VDangel, CBuxton, EBeattie, Met al.Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry 1996;153:711–13Google ScholarPubMed
Frangou, SRaymont, VBettany, DThe Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder. Bipolar Disord 2002;4(6):378–85.CrossRefGoogle ScholarPubMed
Freeman, MPStoll, ALMood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155(1): 12–21.CrossRefGoogle ScholarPubMed
Freeman, TWClothier, JLPazzaglia, PLesem, MDSwann, ACet al.A double-blind comparison of valproate and lithiuim in the treatment of acute mania. Am J Psychiatry 1992;149:108–11.Google ScholarPubMed
Geddes, JGoodwin, GBipolar disorder: clinical uncertainty, evience-based medicine and large-scale randomised trials. Br J Psychiatry 2001;178(41):S191-4.CrossRefGoogle Scholar
Ghaemi, NSachs, GGoodwin, GKWhat is to be done? Controversies in the diagnosis and treatment of manic-depressive illness. World J Biol Psychiatry 2000;1(2):65–74.CrossRefGoogle ScholarPubMed
Goodwin, GHypomama: what’s in a name? Br J Psychiatry 2002;181:94–5.CrossRefGoogle Scholar
Goodwin, GEvidence-based guidelines for treating bipolar disorder. recommendations from the British Association for Psychopharmaco-logy. J Psychopharmacol 2003;17(2):149-73.CrossRefGoogle Scholar
Grunze, HKasper, SGoodwin, GBowden, CBaldwin, DLicht, Ret alWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders, part I: treatment of bipolar depression. World J Biol Psychiatry 2002;3(3):115–24.CrossRefGoogle ScholarPubMed
Grunze, HKasper, SGoodwin, GBowden, CBaldwin, DLicht, Ret al.The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part II: treatment of mania. World J Biol Psychiatry 2003;4(1):5–13.CrossRefGoogle ScholarPubMed
Hirschfeld, RMA. Bowden, CLGithn, MJKeck, PESuppes, TThase, MDPractice guideline for treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002:159(4):1–50.Google Scholar
Licht, RWDrug treatment of mania: a critical review. Acta Psychiatr Scand 1998.97:387–97.CrossRefGoogle ScholarPubMed
Lim, PTunis, SLEdell, WSEndicott, JAkiskal, HMedication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disord 2001;3(4):165–73.CrossRefGoogle ScholarPubMed
Lish, JD Dime-Meenan, SWhybrow, PCPrice, RAHieschfeld, RMThe National Depressive and Manie-Depressive Association (DMDA) survey of bipolar members. J Affective Disord 1994:3(14):281–94.CrossRefGoogle Scholar
Miklowitz, DJGeorge, ELRichards, JASimoneau, TLSuddafh, RLA randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003;60(9):904–12.CrossRefGoogle ScholarPubMed
Muller-Oerlinghausen, BRetzo, AHenn, FGiedke, HWalden, JValproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol 2000;20(2): 195–203.CrossRefGoogle ScholarPubMed
Nemeroff, CBAn ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 2000;61(13):19–25.Google ScholarPubMed
Perry, ATamer, NMorriss, RMcCarthy, ELimb, KRandomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. Br Med J 1999;16:149–53.CrossRefGoogle Scholar
Sachs, GSPrintz, DJKahn, DACarpenter, DDocherty, JPThe Expert Consensus Guideline Series medical treatment of bipolar disorder. Postgrad Med J 2000;(special issue): 1–104.Google ScholarPubMed
Sachs, GGrossman, FOkamoto, AGhaemi, SNBowden, CLRisperidone plus mood stabilizer versus placebo plus mood stabilizer for acute mania of bipolar disorder: a double-blind comparison of efficacy and safety. Am J Psychiatry 2002;159:1146–54.CrossRefGoogle Scholar
Tohen, MChengappa, KNRSuppes, TBaker, RWRisser, RCEvans, ARet al.Olanzopine Combined with Lithium or Valproate in Prevention of Recurrence in Bipolar Disorder : An 18-Month Study Poster presented at the US Psychiatric & Mental Health Congress 2001-November 15–18, 2001 - Boston, 2001 [Abstract].Google Scholar
Suppes, TDennehy, EBSwan, ACBowden, CCalabrese, JHieschfeld Ret al. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002;63(4):288–99.CrossRefGoogle Scholar
Tohen, MKetter, TAZarate, CASuppes, TFrye, MAltshuler, Let al.Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003:160(7): 1263–71.CrossRefGoogle ScholarPubMed
Verdoux, HGonzales, BTakei, NBourgeois, MA survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. J Affective Disord 1996;38(2–3):81–7.CrossRefGoogle ScholarPubMed
Weissman, MMBland, RCCanino, GJFaravelli, CGreenwald, SHwu, HGet al.Cross-national epidemiology of major depression and bipolar disorder. J Am Med Assoc 1996;276(4):293–9.CrossRefGoogle ScholarPubMed
Zarate, CTohen, MLand, MCavanaugh, SFunctional impairment and cognition in bipolar disorder. Psychiatr Quart 2000;71(4):309–29.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.